Shilpa Medicare Ltd announces that the results of its Phase I clinical trials were accepted by Subject Expert Committee (Haematology) (SEC) which has now provided approval to conduct Phase III clinical trials for Recombinant Human Albumin (rHA) 20%. The studies will be conducted based on the approved protocol by SEC.
Shilpa is the first company in India to receive the approval for conducting Phase III clinical trials. This approval clears regulatory strategy for India and various emerging markets that accept Indian studies and is an important step towards providing a reliable and safe alternative to human serum albumin, addressing the global demand and supply challenges.
About Albumin & Recombinant Human Albumin (rHA) 20%:
Albumin is in high demand for various medical treatments, including restoring blood volume and replacing lost fluids during accidents, serious burn injuries, fatal erythroblastosis, hypoproteinemia, and surgeries. However, the supply of human serum albumin is limited due to the reliance on whole blood or donated human plasma. Shilpa's Recombinant Human Albumin 20% (rHA), derived from yeast, offers a highly purified, structurally and functionally equivalent alternative to human serum albumin.
Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 888.80 as compared to the previous close of Rs. 895.20. The total number of shares traded during the day was 13680 in over 944 trades.
The stock hit an intraday high of Rs. 929.95 and intraday low of 880.00. The net turnover during the day was Rs. 12250578.00. |
